recent
year
wit
discoveri
new
mechan
gene
regul
call
rna
interfer
rnai
revit
interest
develop
nucleic
acidbas
technolog
therapeut
gene
suppress
review
focus
potenti
therapeut
use
rnai
discuss
theoret
advantag
rnaibas
therapeut
previou
technolog
well
challeng
involv
develop
rnai
clinic
use
also
review
vivo
proofof
principl
experi
provid
preclin
justif
continu
develop
rnaibas
therapeut
pharmaceut
industri
ongo
interest
develop
technolog
therapeut
gene
suppress
previou
effort
focus
sequencespecif
rna
knockdown
technolog
antisens
oligonucleotid
ribozym
success
achiev
drug
platform
technic
issu
regard
deliveri
stabil
offtarget
effect
effect
target
sequenc
select
slow
develop
efficaci
clinic
drug
recent
year
howev
wit
discoveri
new
mechan
gene
regul
call
rna
interfer
rnai
revit
interest
clinic
develop
nucleic
acidbas
gene
inhibit
approach
review
focus
potenti
therapeut
use
rnai
brief
introduct
rnai
discuss
theoret
advantag
rnaibas
therapeut
previou
technolog
temper
optim
discuss
challeng
involv
develop
rnai
clinic
use
final
review
proofof
principl
experi
demonstr
clinic
potenti
rnai
highlight
vivo
success
provid
preclin
justif
continu
develop
rnaibas
therapeut
rnai
natur
occur
biolog
process
highli
conserv
among
multicellular
organ
divers
plant
worm
yeast
human
refer
twopart
intracellular
pathway
precursor
doublestrand
rna
molecul
present
cell
first
process
dicer
endonucleas
short
nucleotid
fragment
contain
nucleotid
singlestrand
overhang
strand
effector
rna
call
short
interf
rna
sirna
becom
incorpor
rnainduc
silenc
protein
complex
risc
one
strand
unwound
sirna
act
guid
sequenc
target
cleavag
homolog
rna
plant
rnai
play
role
cellular
defens
protect
cell
inappropri
express
repetit
sequenc
transpos
element
viru
infect
review
addit
evid
similar
defens
function
may
still
activ
mammalian
cell
increas
number
short
rna
molecul
found
encod
mammalian
genom
endogen
rna
microrna
mirna
also
process
dicer
sirna
effector
prove
regul
express
gene
involv
varieti
cellular
process
prolifer
apoptosi
differenti
review
importantli
sirna
molecul
chemic
synthes
exogen
introduc
mammalian
cell
becom
incorpor
cellular
risc
complex
mediat
degrad
rna
homolog
abil
tap
nativ
pathway
recogn
one
excit
biotechnolog
advanc
last
decad
inde
rnai
revolution
biolog
research
includ
drug
target
discoveri
allow
rapid
identif
valid
gene
function
alon
justifi
rnai
name
scienc
magazin
mani
hope
greatest
contribut
rnai
yet
come
serv
mean
sequencespecif
therapeut
wide
rang
diseas
sever
compani
focus
develop
rnaibas
therapeut
tabl
one
potenti
advantag
sequencebas
gene
suppress
technolog
abil
design
precis
target
therapeut
almost
gene
regardless
function
gene
product
whether
function
clearli
defin
absenc
protein
structur
inform
particularli
field
oncolog
genet
neurolog
disord
diseas
often
caus
domin
mutat
singl
allel
would
offer
opportun
select
inhibit
express
defect
gene
howev
abl
identifi
effect
target
sequenc
singl
polymorph
distinguish
trivial
impress
although
knowledg
optim
sirna
target
select
still
limit
rnai
activ
specif
enough
allelespecif
silenc
alreadi
demonstr
sever
promin
cancer
neurolog
target
difficult
directli
compar
effici
gene
suppress
technolog
due
differ
rule
optim
design
target
sequenc
select
sever
studi
support
conclus
rnaimedi
inhibit
potent
achiev
antisens
oligonucleotid
even
case
site
select
optim
antisens
effect
review
also
empir
evid
remark
speed
rnai
techniqu
implement
scientif
research
number
success
rnaibas
experi
alreadi
publish
specul
advantag
deriv
fact
rnai
innat
biolog
respons
henc
repres
natur
strategi
manipul
gene
express
event
mean
physiolog
benefici
silenc
achiev
lower
concentr
effector
molecul
review
perhap
due
superior
potenc
also
rel
easi
identifi
effect
rnai
target
site
although
rule
optim
rnai
effect
still
determin
basic
paramet
regard
cg
content
composit
overhang
met
high
percentag
potenti
target
screen
usual
prove
function
hand
significantli
difficult
identifi
effici
antisens
oligonucleotid
target
sequenc
uprichard
unpublish
data
ribozym
target
select
limit
avail
particular
sequenc
motif
requir
cleavag
versatil
eas
rnaimedi
inhibit
induc
mean
multipl
sequenc
within
individu
gene
group
gene
target
simultan
readili
provid
benefit
combin
therapi
problem
deliveri
uniqu
rnai
therapeut
far
major
obstacl
clinic
use
rnaibas
drug
rnai
effector
rnai
effector
deliv
cell
use
two
differ
approach
one
case
sirna
synthes
laboratori
deliv
drug
second
option
gene
therapi
approach
dna
encod
short
hairpin
rna
shrna
express
cassett
deliv
cell
allow
intracellular
express
shrna
process
activ
sirna
host
cell
potenti
advantag
latter
dna
approach
includ
inher
higher
stabil
transient
deliv
plasmid
dna
fact
strategi
consist
intracellular
amplif
step
larg
amount
shrna
synthes
individu
templat
addit
also
possibl
deliv
dna
express
vector
stabli
either
integr
genom
selfrepl
episom
form
theoret
could
allow
constitut
express
shrna
cassett
local
deliveri
base
preced
success
local
administr
antisens
drug
eye
initi
clinic
trial
rnaibas
treatment
agerel
macular
degener
use
local
inject
sirna
directli
eye
promis
local
rout
intranas
administr
pulmonari
deliveri
direct
deliveri
central
nervou
system
nonetheless
rnai
therapeut
overcom
impedi
gene
silenc
technolog
came
effect
system
deliveri
subsequ
target
correct
cell
must
achiev
optim
system
deliveri
requir
stabil
sirna
target
effector
correct
tissu
facilit
cellular
uptak
thu
far
approach
improv
stabil
cellular
uptak
sirna
drug
includ
mani
strategi
employ
antisens
oligonucleotid
direct
chemic
alter
nucleic
acid
variou
method
packag
effector
protect
particl
target
effector
particular
cell
type
differ
ligand
antibodi
incorpor
intoconjug
rnai
effector
continu
work
need
achiev
effici
requir
notabl
use
viral
vector
may
use
system
deliveri
rnai
effector
unfortun
although
viral
vector
provid
excel
tissuespecif
tropism
transduct
effici
need
clinic
deliveri
type
viral
vector
bring
uniqu
set
risk
safeti
concern
review
despit
setback
encount
past
gene
therapi
clinic
trial
howev
need
benefit
rnai
therapeut
compel
case
may
outweigh
risk
henc
lentiviru
adenoassoci
viru
aav
vector
consid
clinic
deliveri
shrna
aim
therapeut
maxim
ratio
desir
effect
undesir
effect
case
chemotherapi
interferon
treatment
highli
activ
antiretrovir
treatment
ratio
ideal
signific
degre
toxic
associ
treatment
rnai
capac
provid
better
gene
target
specif
exposur
cell
exogen
molecul
sirna
deliveri
agent
potenti
perturb
normal
cellular
function
need
care
control
offtarget
effect
specif
one
greatest
advantag
offer
rnai
offtarget
effect
still
potenti
problem
particularli
paramet
determin
minimum
level
homolog
requir
sirna
mediat
inhibit
gene
yet
known
depend
sequenc
sirna
base
pair
homolog
singlestrand
rna
found
result
inhibit
importantli
wealth
searchabl
genet
inform
avail
provid
valuabl
tool
use
tri
avoid
inadvert
offtarget
homolog
rigor
empir
screen
potenti
sirna
effector
continu
necessari
limit
offtarget
effect
nonspecif
effect
issu
nonspecif
toxic
twofold
rnai
deliveri
vehicl
sirna
effector
may
elicit
unexpect
cellular
respons
firstli
found
cation
liposom
use
deliv
sirna
might
induc
potenti
interferon
respons
likewis
viral
vector
might
use
transport
shrna
express
cassett
cell
could
stimul
undesir
vectorspecif
immun
respons
secondli
natur
sirna
effector
may
trigger
induct
doublestrand
rna
cellular
defens
mechan
although
interferon
induct
might
benefici
therapi
instanc
uncontrol
induct
innat
defens
mechan
cytotox
therefor
concern
initi
gene
express
profil
differ
laboratori
provid
conflict
result
regard
whether
interferon
induc
respons
sirna
recent
studi
howev
start
systemat
analyz
differ
reveal
certain
sirna
induc
interferon
respons
other
review
exampl
hornung
et
al
identifi
base
pair
danger
motif
context
sirna
effector
induc
interferon
signal
addit
structur
introduc
sirna
molecul
dictat
whether
interferon
induc
kim
et
al
report
presenc
phosphat
trigger
interferon
induct
consequ
care
design
screen
candid
sirna
deliveri
vehicl
necessari
tri
identifi
minim
potenti
advers
effect
satur
rnai
machineri
eas
effici
sirna
inhibit
may
deriv
fact
exogen
ad
molecul
usurp
natur
cellular
pathway
grow
safeti
concern
could
interfer
regulatori
function
endogen
mirna
known
share
process
machineri
evid
suggest
excess
sirna
deliv
mammalian
cell
intracellular
rnai
process
machineri
becom
satur
conclus
drawn
studi
demonstr
competit
codeliv
sirna
target
two
differ
gene
inhibit
sirna
function
codeliv
scrambl
sirna
begin
appreci
divers
role
mirna
play
mammalian
cell
accumul
data
indic
involv
mani
critic
aspect
gene
regul
review
furthermor
alter
express
mirna
process
machineri
recent
implic
sever
neurolog
diseas
cancer
instanc
express
mirna
found
oncogen
case
reduc
mirna
express
observ
cancer
cell
therefor
import
assess
longterm
consequ
rnai
therapi
order
determin
mirna
function
neg
affect
overcom
problem
might
necessari
analyz
differ
dose
sirna
determin
maximum
capac
intracellular
sirna
process
machineri
differ
cell
type
wide
varieti
issu
ultim
determin
efficaci
particular
rnaibas
therapeut
resist
iron
except
sequencespecif
rnai
also
view
one
potenti
weak
problem
often
cite
discuss
use
rnai
antivir
agent
demonstr
rna
dna
virus
rapidli
gener
rnai
escap
mutat
problem
probabl
necessit
use
rnai
combin
therapi
approach
includ
multipl
rnai
target
sequenc
andor
synergist
antivir
small
molecul
inhibitor
anoth
possibl
issu
regard
viral
resist
discoveri
analog
plant
virus
review
mammalian
virus
nodamura
viru
human
immunodefici
viru
hiv
encod
gene
may
interfer
rnai
silenc
notabl
howev
effect
viral
encod
gene
prevent
therapeut
rnai
inhibit
remain
determin
resist
particular
rna
rnaimedi
degrad
also
observ
case
access
target
sequenc
restrict
cellular
mrna
structur
target
rna
found
affect
silenc
effici
viral
rna
resist
also
relat
intracellular
locat
andor
nucleocapsid
associ
genom
rna
molecul
resist
may
also
fundament
problem
treatment
cancer
alter
express
mirna
process
enzym
dicer
recent
found
associ
differ
type
cancer
possibl
process
machineri
requir
sirna
activ
function
normal
tumor
cell
henc
depend
natur
oncogen
defect
possibl
therapeut
deliv
sirna
may
effect
cell
posit
note
preliminari
studi
demonstr
effect
sirna
multipl
cancer
model
yet
role
mirna
play
oncogenesi
might
impact
sirna
process
area
need
investig
incomplet
inhibit
although
rnai
potent
gene
silenc
method
review
design
rnaibas
therapeut
necessari
consid
quantit
limit
inher
technolog
specif
rnai
knocksdown
gene
express
gener
elimin
condit
partial
regul
pathogen
gene
appear
suffici
produc
clinic
relev
improv
howev
cure
case
genet
diseas
cure
necessarili
expect
condit
cancer
infecti
diseas
ideal
goal
therapi
would
rid
patient
diseas
limit
illustr
sever
xenograph
mous
tumor
model
sirna
silenc
oncogen
vivo
shown
slow
rate
tumor
progress
prolong
surviv
tumor
clear
henc
mani
case
rnai
treatment
strategi
may
effect
design
context
synergist
combinatori
therapi
approach
durat
also
relat
efficaci
durat
therapeut
effect
deliv
drug
sirna
shrnaexpress
dna
templat
function
transient
transfect
cell
cultur
inhibitori
effect
usual
peak
day
posttransfect
fade
thereaft
alter
sirna
stabil
see
may
prolong
effect
absenc
endogen
rnai
mechan
amplif
spread
mammalian
cell
activ
deliv
nucleic
acid
expect
remain
transient
natur
deliv
sirna
part
acut
cur
treatment
transient
activ
might
suffici
case
rnai
suppress
part
longterm
treatment
protocol
requir
frequent
dose
probabl
signific
cost
notabl
desir
develop
rnaibas
therapeut
chronic
condit
genet
defect
one
main
motiv
develop
gene
therapi
deliveri
techniqu
presum
would
allow
constitut
intracellular
express
therapeut
shrna
stabil
although
data
indic
sirna
stabl
serum
mammalian
cell
antisens
oligonucleotid
ribozym
multipl
approach
investig
alter
pharmacokinet
properti
sirna
increas
halflif
vivo
protect
vehicl
liposom
design
escort
target
intact
sirna
effector
cellular
uptak
chemic
modif
sirna
also
investig
mean
directli
stabil
molecul
importantli
sever
group
shown
inhibit
gene
express
sirna
compat
broad
spectrum
chemic
modif
recent
morrissey
et
al
demonstr
combin
direct
modif
improv
stabil
thu
vivo
efficaci
intraven
administ
sirna
howev
determin
author
less
inject
sirna
reach
target
organ
indic
modif
improv
target
andor
cellular
uptak
also
necessari
importantli
despit
challeng
wide
varieti
diseaserelev
gene
specif
inhibit
sirna
shrna
vitro
small
anim
model
tabl
addit
plan
ongo
clinic
trial
soon
provid
valuabl
inform
regard
efficaci
dose
deliveri
safeti
use
continu
advanc
rnaibas
drug
analysi
issu
complianc
factor
success
therapeut
regimen
one
earliest
propos
therapeut
use
rnai
inhibit
viral
infect
sever
compani
develop
rnaibas
therapi
ongo
program
focus
viral
target
tabl
target
viral
rna
mani
report
shown
pretreat
cotreat
virusspecif
sirna
use
inhibit
express
andor
replic
numer
virus
vitro
vivo
review
tabl
particular
investig
potenti
antivir
benefit
rnai
focus
heavili
hiv
review
hepat
virus
review
current
avail
treatment
option
virus
inadequ
furthermor
avail
multipl
welldefin
hbv
mous
model
made
viru
popular
target
vivo
proofofconcept
studi
initi
vivo
hydrodynam
transfect
experi
demonstr
simultan
deliveri
hbv
express
plasmid
hbvspecif
sirna
shrna
express
vector
mous
liver
prevent
induct
hbv
gene
express
replic
expand
studi
other
examin
therapeut
potenti
rnai
treatment
chronic
hbv
infect
use
mous
model
ongo
viral
gene
express
replic
establish
liver
prior
sirna
deliveri
although
shown
viral
rna
resist
silenc
mammalian
virus
like
hiv
may
encod
protein
interfer
rnai
activ
case
hbv
signific
inhibit
viral
gene
express
replic
achiev
therapeut
administr
rnai
effector
differ
mous
model
likewis
inhibit
influenza
viru
coxsackieviru
respiratori
syncyti
viru
rsv
infect
inhibit
sirna
deliv
establish
infect
mice
target
host
cell
gene
virus
rapidli
gener
escap
mutat
sirna
target
directli
genom
anoth
potenti
rnai
antivir
strategi
inhibit
express
cellular
factor
perpetu
infect
particular
hiv
cellular
receptor
appeal
target
inhibit
could
significantli
block
initi
viral
entri
suscept
cell
type
implement
type
indirect
inhibit
approach
howev
would
import
determin
effect
might
occur
result
regul
particular
host
gene
que
atelocollagen
iv
intraven
intratumor
hd
hydrodynam
inject
ata
aurintricarboxyl
acid
carcinoembryon
antigenrel
adhes
molecul
tion
could
limit
feasibl
strategi
virus
term
potenti
viral
clearanc
rnai
knock
viral
rna
alon
unlik
complet
elimin
viral
infect
howev
may
still
prove
effect
antivir
viral
replic
spread
reduc
suffici
allow
endogen
host
immun
respons
success
combat
infect
exampl
case
hbv
even
chronic
infect
patient
maintain
virusspecif
cytotox
lymphocyt
ctl
respons
throughout
cours
infect
although
immun
respons
strong
enough
independ
clear
viru
continu
destroy
cell
express
hbv
antigen
mean
cell
hbv
silenc
would
surviv
advantag
may
select
time
repopul
liver
diseas
diseas
hd
fragil
x
syndrom
amyotroph
later
sclerosi
al
spinobulbar
muscular
atrophi
promin
neurolog
diseas
rnaibas
therapi
might
prove
use
review
tabl
german
common
among
neurodegen
disord
result
domin
mutat
singl
allel
henc
case
sequenc
specif
offer
rnai
may
provid
mean
inhibit
express
mutant
target
gene
allow
essenti
wild
type
allel
express
recent
exampl
abil
sirna
distinguish
singl
nucleotid
differ
wildtyp
mutant
rna
demonstr
model
al
lethal
motor
neuron
degen
diseas
current
treatment
al
result
singl
nucleotid
mutat
gene
encod
cuzn
superoxid
dismutas
ding
et
al
report
sirna
poliiidriven
shrna
could
design
select
silenc
domin
mutant
al
allel
recent
two
report
confirm
effect
approach
transgen
mous
model
al
studi
lentivir
vector
use
deliv
shrna
specif
mutant
intramuscular
intrasplen
inject
result
reduct
mutant
express
lead
prolong
surviv
motor
neuron
delay
onset
al
symptom
increas
lifespan
although
vivo
deliv
shrna
experi
specif
human
transgen
due
sequenc
differ
mous
human
gene
previou
studi
ding
et
al
demonstr
feasibl
distinguish
close
relat
human
allel
term
gener
clinic
applic
howev
bigger
issu
may
al
caus
distinct
mutat
address
issu
xia
et
al
test
replac
rnai
strategi
target
inhibit
mutant
wildtyp
form
simultan
deliv
function
gene
resist
sirna
due
presenc
silent
mutat
gene
therapi
approach
lentiviru
develop
deliveri
sirna
also
possibl
use
type
replac
rnai
strategi
anoth
class
domin
neg
mutant
target
found
least
progress
neurogen
disord
includ
hd
spinocerebellar
ataxia
diseas
caus
polyglutamin
expans
cag
trinucleotid
repeat
found
mutant
allel
diseas
model
hd
mutant
protein
shown
toxic
neuron
repress
mutant
gene
clinic
benefici
revers
motor
dysfunct
two
recent
report
use
aav
vector
express
diseasespecif
shrna
brain
transgen
mice
model
hd
case
express
mutant
gene
reduc
result
improv
behavior
neuropatholog
abnorm
one
caveat
author
acknowledg
studi
due
natur
transgen
model
vivo
deliv
shrna
default
specif
mutant
human
transgen
base
sequenc
differ
mous
human
gene
howev
previou
vitro
studi
demonstr
allelespecif
target
gene
contain
polyglutamin
expans
possibl
interestingli
howev
determin
sirna
target
within
cag
repeat
region
necessarili
result
allelespecif
inhibit
author
demonstr
sirna
could
design
distinguish
allel
base
associ
singlenucleotid
polymorph
snp
may
may
function
contribut
diseas
phenotyp
addit
target
domin
mutant
allel
rnaibas
approach
could
also
prove
use
treatment
form
neurolog
diseas
inhibit
specif
processingregulatori
pathway
requir
exampl
caus
increas
bamyloid
product
requir
cleavag
bsecretas
enzym
regul
brain
patient
henc
sirna
target
downregul
may
abl
halt
progress
proof
concept
kao
et
al
use
rnai
inhibit
express
primari
mous
cortic
neuron
observ
expect
decreas
bamyloid
product
similarli
learn
molecular
mechan
mediat
neurotox
acut
advers
neurolog
event
stroke
spinal
cord
injuri
like
target
identifi
minim
event
lead
neuron
damag
facilit
restor
process
convent
chemotherapi
proven
effect
mean
kill
cancer
cell
lack
select
requir
distinguish
tumor
cell
normal
cell
result
signific
degre
collater
cell
death
therefor
therapi
could
target
specif
cancer
cell
would
provid
attract
treatment
option
effici
deliveri
target
ongo
issu
develop
rnaibas
drug
potenti
util
rnai
inhibit
cancer
cell
prolifer
recent
demonstr
mani
vitro
well
vivo
studi
tabl
review
direct
target
oncogen
abil
sirna
discrimin
mutant
wild
type
allel
present
advantag
field
oncolog
domin
mutant
neurodegen
disord
discuss
multipl
oncogen
gene
fusion
form
chromosom
transloc
leukemia
lymphoma
readili
inhibit
rnai
approach
vitro
review
stringent
allelespecif
target
achiev
sever
singl
nucleotid
mutant
form
ra
preval
human
cancer
drug
sensit
although
direct
inhibit
oncogen
may
slow
tumor
growth
elimin
cancer
cell
furthermor
reduc
rate
tumor
cell
prolifer
might
expect
reduc
effect
tradit
therapi
preferenti
target
activ
divid
cell
henc
potenti
use
rnai
facilit
effect
tradit
cancer
therapeut
propos
exampl
target
suppress
antiapoptot
gene
sensit
cell
chemotherapi
agent
etopodis
daunorubicin
likewis
sirna
silenc
doublestrand
break
repair
protein
dnadepend
protein
kinas
catalyt
subunit
confer
enhanc
radio
chemosensit
tumor
cell
rnai
might
also
complement
chemotherapi
treatment
patient
develop
multidrug
resist
cancer
patient
develop
resist
chemotherapeut
agent
due
express
multidrug
resist
gene
rnaimedi
suppress
shown
resensit
cell
effect
chemotherapi
henc
rnai
effector
could
specif
deliv
tumor
cell
could
made
preferenti
sensit
tradit
cancer
therapi
inhibit
invas
migrat
final
anoth
cancer
treatment
approach
investig
use
rnai
indirectli
control
tumor
growth
inhibit
process
requir
tumor
spread
exampl
case
breast
cancer
transform
cell
express
chemokin
receptor
promot
metastasi
organ
abund
ligand
sever
group
shown
rnaimedi
inhibit
result
reduc
cell
invas
vitro
well
block
breast
cancer
metastasi
xenograph
anim
model
gener
approach
member
vascular
endotheli
growth
factor
vegf
famili
involv
gener
new
blood
vessel
requir
tumor
growth
test
potenti
anticanc
treatment
target
review
transplant
tumor
cell
subcutan
mice
two
group
shown
intratumor
inject
vegfspecif
sirna
either
nake
complex
atelocollagen
block
angiogenesi
limit
tumor
growth
recent
schiffel
et
al
achiev
similar
result
deliv
vegf
receptorspecif
sirna
xenograph
tumor
intraven
inject
ligandtarget
stabil
nanoparticl
angiogenesi
addit
causal
role
sever
ocular
diseas
includ
agerel
macular
degener
amd
herpet
stromal
kerat
diabet
retinopathi
vegf
found
directli
involv
destruct
vascular
associ
ocular
diseas
abil
vegfspecif
sirna
reduc
vegfdepend
vascular
invas
eye
demonstr
anim
model
tabl
phase
amd
clinic
trial
patient
ongo
well
notabl
howev
compet
technolog
area
antivegf
aptam
therapeut
pegaptanib
sodium
approv
treatment
amd
decemb
diseas
patholog
observ
caus
activ
innat
cellular
process
henc
target
key
molecul
involv
pathway
rnai
therapeut
may
provid
mean
control
cellular
process
respons
exampl
tumor
necrosi
factor
tnf
proinflammatori
cytokin
involv
chronic
pathogenesi
rheumatoid
arthriti
ra
drug
current
use
block
action
tnfa
shown
effect
reduc
inflamm
slow
ra
progress
sever
risk
congest
heart
failur
demyelin
diseas
system
lupu
erythematosu
lymphoma
seriou
infect
associ
use
system
tnfablock
preclin
mous
model
collagen
induc
arthriti
schiffel
colleagu
recent
demonstr
local
inject
electropor
tnfaspecif
sirna
effect
inhibit
paw
inflamm
mice
furthermor
use
intraven
inject
luciferas
report
author
subsequ
show
joint
inject
electropor
luciferasespecif
sirna
inhibit
report
gene
local
studi
suggest
lieu
convent
antitnfa
blocker
local
deliveri
tnfaspecif
sirna
might
provid
safer
mean
reduc
inflamm
ra
patient
mani
propos
rnai
therapeut
target
relat
chronic
andor
progress
diseas
import
note
rnai
could
also
potenti
serv
valuabl
function
limit
acut
respons
well
mous
model
sepsi
shown
pretreat
tnfaspecif
sirna
inject
intraperiton
abl
increas
surviv
rate
sixfold
lethal
lipopolysaccharid
challeng
similarli
one
first
experi
demonstr
therapeut
potenti
rnai
use
fasspecif
sirna
protect
mice
fulmin
hepat
anoth
studi
report
caspas
sirna
treatment
also
prevent
acut
liver
failur
studi
illustr
concept
sirna
might
use
effect
control
acut
respons
whether
mean
limit
danger
uncontrol
inflamm
prevent
hepatocyt
apoptosi
preserv
liver
function
tabl
although
complet
list
potenti
therapeut
applic
rnai
intend
illustr
advantag
inher
rnai
technolog
specif
potenc
versatil
could
possibl
translat
signific
progress
molecular
medicin
howev
import
also
revisit
sober
challeng
face
sequencespecif
gene
silenc
technolog
deliveri
safeti
efficaci
make
predict
futur
promis
yet
immatur
technolog
fortuit
develop
rnai
technolog
facilit
mani
year
previou
research
antisens
drug
deliveri
enorm
amount
genet
inform
recent
obtain
human
genom
project
converg
event
momentum
alon
seem
provid
extra
push
could
make
leap
forward
possibl
